Physician profile
Biresh Kumar
NPI 1558341909
$901.40
in general payments reported to CMS, 2019-2025
11 companies · $65.50 in 2025
The $65.50 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $50.13 · 2021: $278 · 2022: $49.56 · 2024: $203 · 2025: $65.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $219.83 | 2019-2024 | Veltassa |
| Aurinia Pharma U.S., INC. | $174.83 | 2021-2024 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $174.15 | 2019-2024 | Lokelma |
| Nxstage Medical, INC. | $135.29 | 2024-2025 | Nxstage System One |
| Amgen INC. | $62.24 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $31.14 | 2024 | |
| Travere Therapeutics, INC. | $29.90 | 2024 | |
| Alexion Pharmaceuticals, INC. | $26.22 | 2019 | |
| Akebia Therapeutics INC | $21.30 | 2022 | |
| Shire North American Group INC | $14.88 | 2019 | |
| Bard Peripheral Vascular, INC. | $11.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biresh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.